Driving Strategic Diagnostic Planning for a Targeted Therapy in Gender-specific Cancer

The Challenge

A top 10 global pharmaceutical company was preparing to launch a precision therapy for a gender-specific cancer, built around an actionable biomarker with the potential to transform patient outcomes. Although the clinical utility and relevance of the biomarker were well established within this cancer type, the opportunity lay in broadening awareness beyond its more familiar components to encompass the full spectrum of relevant genetic alterations essential for therapy eligibility.

Key Issues:

• Assumed consistency in biomarker testing masked significant variability across global healthcare systems, revealing gaps in readiness for this specific cancer
• Limited visibility into diagnostic readiness in priority markets beyond the already established components of the biomarker
• While the global strategy provided a strong foundation, its local application required more adaptable, region-specific tactics to drive testing uptake effectively.

Our Approach

Diaceutics partnered with the company to deliver a multi-phase diagnostic enablement strategy. This began with a U.S.-focused 6A™ Strategic Landscape analysis, leveraging real-world data and expert insights to map current testing practices and identify key barriers. A strategic playbook was developed to guide internal teams in executing targeted patient identification initiatives.

Building on this foundation, the strategy was expanded to key EU and APAC markets, enabling global diagnostic planning tailored to local needs. Diaceutics facilitated cross-functional workshops to align implementation tactics and supported ongoing collaboration through educational programs, physician segmentation, and clinical trial planning.

The Impact

The Diaceutics 6A™ Strategic Landscape uncovered critical gaps in biomarker testing across global markets and enabled the client to implement targeted solutions that improved internal coordination, testing awareness, and diagnostic readiness.

• Awareness, Availability and Access

• Identified as three critical diagnostic barriers and proactively addressed as part of the global launch strategy.

• Doubled Awareness Among Key Physician Groups

• Targeted engagement achieved email open rates of more than 30% (twice industry benchmarks).

Testimonial

"Diaceutics demonstrated deep expertise in diagnostic strategy and commercialization. They provided country-level clarity, including reimbursement insights, which added valuable depth to our planning. The collaboration was seamless and fast-moving, with highly interactive and responsive delivery across our regional teams. Among the vendors we work with, Diaceutics stands out for their strategic focus, diagnostic expertise, and quality of execution."

- Global marketing director from top 10 global pharma

About Diaceutics

At Diaceutics, our vision is Precision for All: a future where every eligible patient is identified, diagnosed, and receives the right therapy at the right time.

For more than 20 years, we have helped biopharma companies overcome the diagnostic and commercialization barriers that stand between scientific innovation and patient impact. Today, we combine diagnostic intelligence, expert insight, and targeted engagement to unlock the full potential of diagnostic-driven therapies—and more life for the patients they are designed to serve.